Spero posts Q4 net income $31.5M; tebipenem HBr PDUFA set for June 18, 2026

Spero Therapeutics, Inc.

Q4 2025 net income $31.5M (vs $20.9M loss); diluted EPS $0.53.
Full year 2025 net income $8.6M (vs $68.6M loss); diluted EPS $0.15.
Total revenue Q4 $41.3M (vs $15.0M); full year $66.8M (vs $48.0M).
Tebipenem HBr NDA resubmitted; FDA PDUFA date June 18, 2026, per partner GSK.
Cash $40.3M sufficient into 2028; received $25M milestone from GSK in Q1 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spero Therapeutics, Inc. reported the year ended December 31, 2025 results: revenue $66.8 million, net income $8.6 million, EPS $0.15.

Period: the year ended December 31, 2025
Revenue: $66.8 million
Net income: $8.6 million
EPS: $0.15
Result: reported results

Exact text from the filing

fourth quarter of 2025 was primarily due to an increase in collaboration revenue from our agreements with GSK and Pfizer. Total revenue for the year ended December 31, 2025, was $66.8 million, compared to $48.0 million for the year ended December 31, 2024. The revenue increase for the year was primarily due to the aforementioned collaboration revenue related to our

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spero Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $41.3 million, net income $31.5 million, EPS $0.53.

Period: the fourth quarter and full year ended December 31, 2025
Revenue: $41.3 million
Net income: $31.5 million
EPS: $0.53
Result: reported results

Exact text from the filing

diluted net gain per share of common stock of $0.15 and a diluted net loss per share of common stock of $(1.27), respectively. • Total revenue for the fourth quarter of 2025 was $41.3 million, compared to total revenue of $15.0 million for the fourth quarter of 2024. The revenue increase for the fourth quarter of 2025 was primarily due to an increase in collaboration

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-126244

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.